Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma

Craig Moskowitz • 9 Apr 2015
ASH 2014
Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Pembrolizumab

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

More from Craig Moskowitz

7:27
Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma
Craig Moskowitz • 5 Dec 2014
23:35
ASH 2014: Ask the experts Q&A session 1
Catherine Bollard et al. • 6 Dec 2014

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals